Non-muscle-invasive bladder cancer (NMIBC) has a high risk of recurrence and progression among patients without adequate Bacillus Calmette-Guérin.
A new study suggests that a urine-based biomarker test shows promise in forecasting bladder cancer treatment response, which ...
Enrollment of BCG naïve subjects (QUILT-2.005) receiving BCG alone versus BCG plus ANKTIVA exceeding expectations 85% enrolled with anticipated completion in Q2 2026 with BLA filing to U.S. Food and ...
Pathologic response and safety of neoadjuvant pembrolizumab with or without entinostat in muscle-invasive urothelial cancer (MIUC). Subsequent line of treatment for BCG unresponsive HR NMIBC patients ...
Research at Stanford Medicine suggests that a urine test may. be able to determine which patients will benefit from additional therapy.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results